Streetwise Reports' Article Archives — August 2021 back to current month (33)
"This marks the first regulatory approval of an OmniAb antibody discovery engine-derived antibody since Ligand Pharmaceuticals first acquired the technology in 2016," noted an H.C. Wainwright & Co. report.
AC Immune SA shares set a new 52-week intraday high after the company reported positive cognitive results for tau-targeting monoclonal antibody semorinemab in a clinical study of patients with mild-to-moderate Alzheimer's disease.
The progress Can-Fite BioPharma made with these studies is briefly summarized in a Dawson James Securities report.
An H.C. Wainwright & Co. report noted that Carmat's Aeson implant "could save many patients who may die, due to [a] shortage of donor hearts, while waiting for a heart transplant."
Shares of Poseida Therapeutics traded 10% higher after the company reported that the U.S. Food and Drug Administration granted clearance for its Investigational New Drug Application for P-BCMA-ALLO1, an allogeneic CAR-T candidate for use in treating relapsed/refractory multiple myeloma.
Shares of Bolt Biotherapeutics Inc. traded nearly 10% higher after the company reported it is collaborating with Innovent Biologics to develop three new oncology Boltbody™ ISAC programs.
An H.C. Wainwright report noted that "this deal is an opportunity for STRATA Skin Sciences to substantially increase its long-term, recurring revenue base."
A BTIG report noted that Legend Biotech's cilta-cel has the potential "to take significant market share within the relapsed-refractory multiple myeloma market and establish a best-in-class profile."
Studies suggest that Galmed Pharmaceuticals' Amilo-5MER has "therapeutic potential in a number of inflammatory diseases," according to an H.C. Wainwright & Co. report.
Trillium Therapeutics shares traded 190% higher after the company reported it agreed to be acquired by pharmaceutical giant Pfizer Inc. for $18.50 per share in cash.
A ROTH Capital Partners report noted that Assertio Therapeutics' business model is starting to gain traction.
Shares of natural cannabis firm Flora Growth Corp. rose 43% after the company reported H1/21 financial results and indicated it expects H2/21 revenues will be in the range of US$9-11 million.
Inovalon Holdings Inc. shares traded 8% higher after the cloud healthcare technology platform firm reported it entered into an agreement to be acquired by an equity consortium led by Nordic Capital and Insight Partners for $41.00 per share in cash.
An H.C. Wainwright & Co. report noted Oncolytics Biotech's overall pelareorep program is on track with several near-term catalysts expected.
Paradigm Capital Inc. stated in a research report that Knight Therapeutics Inc. posted significantly better than expected operating and financial results in Q2/21 that greatly exceeded analysts' estimates. Meanwhile, insiders continue to add to their positions, and the company has filed a new NCIB allowing it to purchase up to 10% of the float during the next 12 months.
Dawson James Securities Inc. stated in a research update that Fortress Biotech Inc.'s dermatology business shows good growth potential and helped drive a positive revenue surprise in Q2/21. Dawson James has a "Buy" rating on the stock but noted that the real opportunity for the company lies with its vast pipeline and partnerships, which offer real upside potential.
Promising early results and a new line of equity support Avisa Diagnostic’s drive for IDE approval of its rapid-response breath test for pneumonia, TB, CF, and other lung ailments.
Gross sales of Stem Holdings dba Driven by Stem during the quarter were 104% higher than they were a year ago.
Travere Therapeutics shares traded 14% higher after the company reported positive interim results from its ongoing Phase 3 PROTECT study of sparsentan in treating IgA nephropathy, a chronic kidney disease that can lead to end-stage renal disease.
Shares of Clover Health Investments Corp. traded higher after the company reported Q2/21 financial results that included a 140% increase in YoY revenue.
A BTIG report noted that CTI Biopharma's Pacritinib "has the potential to be a lead therapeutic in the myelofibrosis space and in additional indications that could provide material value to CTI and CTI's shares over time."
Behind that forecast, in part, are positive cannabis legislative developments and increasing consumer cannabis use, which are covered in a ROTH Capital Partners report.
The Liquid Avatar Credential Ecosystem, or LAVCE, is designed to carry a secure, digital record of a person’s verifiable COVID-19 testing credentials, and future healthcare applications of the technology are expected.
Algernon Pharmaceuticals reported its acquisition of the exclusive rights from Dartmouth College for a method of use patent for use in treatment of neuroendocrine cancers expressing functional NMDA receptors.
Fulcrum Therapeutics shares rose 125% and set a new 52-week high after the company reported Q2/21 financial results and released positive interim results from its Phase 1 sickle cell disease trial.
Shares of Cortexyme Inc. traded 47% higher to a new 52-week high after the company reported Q2/21 financial results and provided an update regarding its ongoing Alzheimer's and periodontal disease clinical trials.
Shares of STAAR Surgical Co. traded 20% higher after the company reported Q2/21 financial results highlighting a 93% YoY increase in net sales of its Implantable Collamer® Lenses.
An H.C. Wainwright & Co. report notes that Agios Pharmaceuticals "is rapidly rebooting and has made critical progress on various fronts."
Biopharma Makes 'Solid Clinical Progress' in Q2/21 (08/04/2021)
The highlights of Oryzon Genomics' Q2/21 clinical advancements were recapped in a Roth Capital Partners report.
Novavax Inc. shares traded nearly 19% higher after the company reported the finalization of an advance purchase agreement with the European Commission to provide up to 200 million doses of its COVID-19 Vaccine.
Shares of Translate Bio Inc. soared to a new 52-week high after the company reported it agreed to be acquired by its collaborative partner Sanofi SA for $38 per share in cash in a deal valued at $3.2 billion.
McAlinden Research Partners explores the acceleration of gene-editing technology and notes the market is poised to expand as the World Health Organization (WHO) creates new standards for companies to follow.
Shares of Annovis Bio Inc. traded 20% higher after the company reported positive interim data from its Phase 2 clinical studies of ANVS401 (Posiphen) for treatment of Alzheimer's and Parkinson's diseases.
|"Experiments showed that PMN's PMN310 has a unique binding profile."|